NCT06735690View on ClinicalTrials.gov

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 23, 2025

Primary Completion Date

March 7, 2029

Study Completion Date

March 7, 2029

Conditions
Acute Lymphoblastic Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo alloHSCT

BIOLOGICAL

Anti-CD19-CAR CMV-specific T-lymphocytes

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood and optional CSF sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Transplant Conditioning

Given HSCT conditioning regimen

PROCEDURE

X-Ray Imaging

Undergo chest x-ray

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER